Format

Send to

Choose Destination
Eur J Cancer Care (Engl). 2007 May;16(3):258-62.

Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer.

Author information

1
Department of Clinical Medicine, University of Roma La Sapienza, Italy. Fabriziofranchi@interfree.it

Abstract

Among a large series of cancer patients treated with a combination of chemotherapy and sessions of hyperthermia, particular attention was given to a specific group of patients with advanced cancer who refused standard, aggressive, treatment. In these cases, hyperthermia was associated to low-dose (metronomic) chemotherapy. No toxicity was reported in any of our patients, while a marginal benefit in terms of tumour progression was observed. During therapy, we could detect a coagulative perturbation that deserves careful discussion. In our opinion, this experience should be matter of debate to conclude if current response criteria (WHO/UICC and RECIST) in treating cancer patients are really suitable tools to evaluate new, and non-aggressive anticancer strategies.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center